Teleflex Inc focuses on medical devices as investors watch long term growth
Teleflex Inc. is a global medical technology company specializing in devices for critical care and surgical procedures. The company's diversified portfolio, focus on innovation, and presence in high-demand segments like vascular access position it for long-term growth, making it an attractive prospect for investors interested in the healthcare sector. Its strategy includes continuous product improvement and R&D investments to expand into higher-value medical device markets.
The Teleflex Arrow EZ-IO System. A rugged emergency access tool built for seconds
The Teleflex Arrow EZ-IO System is an intraosseous vascular access device designed for rapid delivery of medications and fluids directly into bone marrow when traditional IV access is difficult. It is widely used by first responders and medical professionals in emergency situations, particularly in the US, and is known for its practicality and effectiveness. The system's reliability and ease of use in critical moments make it a staple in emergency medicine, contributing to Teleflex's vascular access portfolio.
Teleflex Q1 2026 slides: earnings beat amid margin pressure, buyback starts early
Teleflex (NYSE: TFX) exceeded Q1 2026 earnings and revenue expectations despite significant margin pressure from tariffs and integration costs. The company reported adjusted EPS of $1.39 and revenue of $548.3 million, driven by strong performance in the Surgical segment and the recent Vascular Intervention acquisition. Teleflex also announced new leadership, governance enhancements, and an accelerated $1 billion share repurchase authorization starting in Q2 2026, while maintaining its full-year 2026 guidance.
If You Invested $1,000 in Teleflex Inc (TFX)
This article analyzes the historical performance of investing $1,000 in Teleflex Inc (TFX) over 1, 5, and 10 years, showing varying returns and underperformance compared to the S&P 500. It also provides an overview of Teleflex Inc, a global medical technology company, detailing its business focus, therapy areas, key brands, strategic actions, leadership changes, clinical research, dividend practices, financial reporting, and regulatory considerations. The company has recently undertaken portfolio reshaping, including divestitures, to focus on core critical care and high-acuity hospital markets.
TFX - Teleflex Incorporated Earnings
This article provides a comprehensive snapshot of Teleflex Incorporated (TFX) financial data and key performance indicators. It covers market valuation, income statement figures, dividend information, analyst estimates, insider and institutional ownership, and various stock performance metrics. The data reflects the company's financial health and market activity up to the last close on July 2nd.
Teleflex Dodges Bid to Revive Patent Case Over Laryngoscopes
Teleflex Medical Inc. successfully fended off an attempt to revive a patent infringement lawsuit concerning its video laryngoscopes. The US Court of Appeals for the Federal Circuit affirmed that the medical device did not infringe on Jonathan Berrall's patent under the doctrine of equivalents, as the arguments failed to meet the specific evidentiary requirements. A North Carolina federal court had previously ruled against literal infringement because the camera mechanism differed from the patent's claims.
Teleflex Dodges Bid to Revive Patent Case Over Laryngoscopes
Teleflex Medical Inc. has successfully fended off an attempt to revive a patent infringement lawsuit concerning its video laryngoscopes. The US Court of Appeals for the Federal Circuit affirmed that inventor Jonathan Berrall's arguments did not meet the specific evidentiary requirements for proving infringement under the doctrine of equivalents. The original ruling by a North Carolina federal court found no literal infringement because the camera in Teleflex's device is fastened to the interior of the camera stick.
Teleflex Inc. stock underperforms Thursday when compared to competitors despite daily gains
Teleflex Inc. (TFX) shares rose 3.27% to $133.99 on Thursday. This gain occurred during a mixed trading session where the S&P 500 remained mostly unchanged and the Dow Jones Industrial Average rose. Despite its daily gains, the stock underperformed compared to its competitors.
Teleflex Inc. stock outperforms competitors on strong trading day
Teleflex Inc. (TFX) shares rose 2.36% to $129.75 on Wednesday, outperforming the broader market during a grim trading session. The S&P 500 Index and Dow Jones Industrial Average both experienced declines, while Teleflex's stock broke a two-day losing streak.
Teleflex Inc. focuses on medical devices as investors watch long-term growth prospects
Teleflex Inc. is a global medical technology company specializing in disposable and specialty devices for hospitals and clinics. The company aims to balance consistent demand in core procedures with investments in new product areas and efficiency initiatives. Its broad portfolio, geographic reach, and focus on consumable products contribute to recurring revenue, positioning it within the medical technology sector as investors evaluate its long-term growth driven by demographic trends and healthcare efficiency.
Teleflex Incorporated (TFX) Stock Price Today
This article provides current market data for Teleflex Incorporated (TFX), including its stock price of $129.25, a market capitalization of $5.72 billion, and a daily trading volume of $44.65 million. The stock has seen a 2.36% movement in the last day. The page also lists performance data and compares TFX with other popular real-world assets.
Teleflex Inc. stock underperforms Monday when compared to competitors
Teleflex Inc. (TFX) shares fell 1.83% on Monday, closing at $127.49, despite a generally positive trading session for the broader stock market. The S&P 500 Index rose 1.18% and the Dow Jones Industrial Average increased by 0.59%. This decline ended a four-day winning streak for Teleflex.
Should Teleflex’s Bioresorbable Scaffold Trial Progress Require Action From Teleflex (TFX) Investors?
Teleflex Incorporated has advanced its Freesolve Resorbable Magnesium Scaffold program with the launch of the BIOMAG-III pivotal trial, early completion of BIOMAG-II enrollment, and positive four-year results from BIOMAG-I. These milestones aim to position bioresorbable scaffolds as a key treatment in interventional cardiology. However, investors should consider the company's increased leverage from new debt, which supports these trials and BIOTRONIK integration, but could magnify risks if earnings remain soft or integration faces delays.
Should Teleflex’s Bioresorbable Scaffold Trial Progress Require Action From Teleflex (TFX) Investors?
Teleflex Incorporated has advanced its Freesolve Resorbable Magnesium Scaffold program with the launch of the BIOMAG-III pivotal trial and encouraging results from earlier studies, aiming to position bioresorbable scaffolds against drug-eluting stents. This progress is important for Teleflex's investment narrative, which relies on innovation and growth despite challenges in its base business and the integration of BIOTRONIK. Investors should consider the implications of increased leverage from new debt on future earnings and valuation.
Enterprise value to EBITDA forward of Teleflex Incorporated – NYSE:TFX
This article focuses on the enterprise value to EBITDA forward for Teleflex Incorporated (NYSE: TFX). It indicates that the company's financial data is available for analysis, likely on the TradingView platform. The content is primarily a placeholder for financial metrics, signaling where users can find detailed information on this specific valuation ratio for Teleflex.
Bronstein, Gewirtz & Grossman, LLC Encourages Teleflex Incorporat
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Teleflex Incorporated (TFX) securities. This investigation follows the immediate departure of Teleflex's Chairman, President, and CEO, Liam Kelly, which led to a significant drop in the company's stock price. The firm is encouraging affected investors to inquire about the securities investigation and explore potential claims.
Enterprise value to EBITDA forward of Teleflex Incorporated – BX:TBH
The article focuses on the "Enterprise value to EBITDA forward" metric for Teleflex Incorporated (BX:TBH), listed on the BX Swiss exchange. It appears to be a financial data page from TradingView, indicating that the market is currently closed and no trades have occurred for this specific metric.
Price to sales forward of Teleflex Incorporated – NYSE:TFX
This page provides the "Price to sales forward" financial metric for Teleflex Incorporated (NYSE: TFX). The content indicates that the market is currently closed, and it also includes various navigational and informational links related to TradingView, financial data providers, and company details.
Teleflex Inc. stock underperforms Friday when compared to competitors despite daily gains
Teleflex Inc. (TFX) stock rallied 1.62% on Friday, closing at $129.86, marking its fourth consecutive day of gains. However, this performance underperformed the broader market, as the S&P 500 Index (SPX) fell 0.05% and the Dow Jones Industrial Average (DJIA) fell 0.09% on the same day.
Teleflex Incorporated Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh
This page provides financial information for Teleflex Incorporated Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh (T1FX34) on the B3 exchange. It specifically focuses on the Enterprise value to EBITDA forward metric for the company. The content appears to be from a financial data platform, showing an overview, financials, news, and technical analysis options, though most sections are placeholders.
Enterprise value to EBIT forward of Teleflex Incorporated – NYSE:TFX
The article "Enterprise value to EBIT forward of Teleflex Incorporated – NYSE:TFX" from TradingView is a financial data page presenting the enterprise value to EBIT forward metric for Teleflex Incorporated (TFX). It provides financial data for the company, accessible through a trading platform. The content is primarily a data point display within a larger financial analysis tool.
Teleflex Incorporated Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh
This article provides an overview of financial actuals and estimates for Teleflex Incorporated Shs Unsponsored Brazilian Depositary Receipt (T1FX34) on the B3 exchange. It details where users can explore reported financial data and analyst estimates across various financial statements and valuation metrics. The information is presented with a disclaimer clarifying that it is not investment advice.
Price to earnings forward of Teleflex Incorporated – NYSE:TFX
This article provides a brief overview of the "Price to earnings forward" metric for Teleflex Incorporated (NYSE: TFX), indicating that the data is presented without specific values or changes. It highlights the company's listing on the New York Stock Exchange and notes that the market is currently closed with no trades.
Teleflex Incorporated Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh
This article provides financial information for Teleflex Incorporated Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh (T1FX34) on TradingView. It specifically highlights the "Price to sales forward" metric for this B3-listed stock. The page indicates that the market is currently closed with no trades.
Teleflex Inc. stock underperforms Thursday when compared to competitors despite daily gains
Teleflex Inc. (TFX) stock increased by 1.01% on Thursday, closing at $127.79. Despite this gain, the stock underperformed compared to its competitors, as the broader market saw mixed results with the Dow Jones Industrial Average rising and the S&P 500 Index slightly falling. This marked the third consecutive day of gains for Teleflex Inc.
Enterprise value to revenue forward of Teleflex Incorporated – BX:TBH
This article provides a financial data point for Teleflex Incorporated (BX:TBH), specifically its enterprise value to revenue forward. The data indicates the period, value, and change percentage for this financial metric. The information is presented by TradingView, with market data from ICE Data Services and reference data from FactSet.
Teleflex Inc. stock outperforms competitors on strong trading day
Teleflex Inc. (TFX) shares rose 1.81% to $126.51 on Wednesday, outperforming the broader market. This marked the stock's second consecutive day of gains, despite a mixed trading session where the Dow Jones Industrial Average rose and the S&P 500 Index fell.
Do Options Traders Know Something About Teleflex Stock We Don't?
This article discusses the high implied volatility in Teleflex (TFX) options, particularly the July 17, 2026 $90.00 Call. It explores what implied volatility signifies for potential stock movement and considers analyst opinions, noting that while options traders anticipate a big move, Teleflex currently holds a Zacks Rank #3 (Hold) with recent downward revisions in earnings estimates by analysts. The article suggests this high implied volatility could present a trading opportunity for seasoned traders to sell premium.
Do Options Traders Know Something About Teleflex Stock We Don't?
Options traders are showing significant interest in Teleflex Incorporated (TFX) as indicated by the high implied volatility of its July 17, 2026 $90.00 Call options. This suggests expectations of a big price movement, though Teleflex is currently a Zacks Rank #3 (Hold). Analysts have recently lowered earnings estimates, leading to a Zacks Consensus Estimate of $1.28 per share for the current quarter.
Teleflex Inc. stock underperforms Tuesday when compared to competitors despite daily gains
Teleflex Inc.'s stock (TFX) rose 2.13% on Tuesday, closing at $124.26, despite a general market downturn. The company's stock underperformed compared to its competitors and finished 11.03% below its 52-week high reached in April. This occurred as the S&P 500 Index fell 1.44% and the Dow Jones Industrial Average dropped 0.09%.
Teleflex begins enrollment in BIOMAG-III pivotal study
Teleflex Incorporated has initiated patient enrollment in the BIOMAG-III Study, a global pivotal trial evaluating its Freesolve Resorbable Magnesium Scaffold. The study aims to enroll 1,859 patients worldwide to compare the Freesolve RMS against the Xience Drug-Eluting Stent in terms of target lesion failure at 12 months. This trial will provide critical evidence for regulatory applications and further the development of resorbable scaffold technology, building on positive long-term data from earlier studies.
Teleflex Starts Enrollment in Resorbable Magnesium Scaffold Study
Teleflex has initiated enrollment for its BIOMAG-III study, a randomized controlled trial evaluating its Freesolve resorbable magnesium scaffold (RMS) against the Xience drug-eluting stent. The study aims to enroll 1,859 patients globally to compare target lesion failure rates at 12 months. This comes after positive long-term data from the BIOMAG-I study and ahead of the BIOMAG-II study results, with the goal of providing pivotal evidence for the Freesolve RMS technology.
Teleflex Initiates Enrollment in Global BIOMAG™‑III Pivotal Trial of Freesolve™ Resorbable Magnesium Scaffold
Teleflex Incorporated has announced the start of enrollment in the global BIOMAG™‑III Study, a pivotal trial evaluating its Freesolve™ Resorbable Magnesium Scaffold (RMS). This study, expected to enroll 1,859 patients across 120 sites worldwide, aims to support future regulatory applications and demonstrate the long-term safety and efficacy of the fully resorbable scaffold. The announcement follows the successful completion of enrollment for the BIOMAG™-II Study and positive four-year results from the BIOMAG™-I First-In-Human Study, highlighting the potential of Freesolve™ RMS to change coronary intervention.
Teleflex Inc (TFX) Financial Health: Profitability & Balance Sheet Analysis
Teleflex Inc (TFX) has a weak financial score of 5.57, ranking 196 out of 203 in the Healthcare Equipment & Supplies industry, despite having high operating efficiency. The company recently reported a 21.75% year-over-year decrease in quarterly revenue and a 108.58% decrease in net profit. Many key financial data points for its quality of earnings, operational efficiency, growth potential, and shareholder returns have not yet been disclosed.
Teleflex Inc (TFX) Shares Fall 4.2% -- What GF Score of 76 Tells Investors
Teleflex Inc (TFX) experienced a 4.2% drop in shares, closing at $121.67, despite being flagged as "significantly undervalued" by GuruFocus's GF Value, which estimates its intrinsic value at $179.12. The company holds a GF Score of 76/100, indicating above-average potential with strong valuation but moderate financial strength and growth scores. Investors are advised to be cautious due to past volatility, as there have been no insider transactions in the last three months, suggesting a wait-and-see approach from insiders.
Teleflex Inc. stock underperforms Monday when compared to competitors
Teleflex Inc. (TFX) stock fell 4.20% on Monday, closing at $121.67, underperforming its competitors and the broader market indices. The Dow Jones Industrial Average rose, while the S&P 500 Index declined slightly. The company's stock is currently 12.89% below its 52-week high.
How Investors Are Reacting To Teleflex (TFX) $500 Million 5.875% Senior Notes To Fund Transformation
Teleflex recently issued $500 million in 5.875% senior notes to fund its transformation, which comes after reporting revenue ahead of expectations but weaker earnings. This move increases interest costs and refines its debt stack, making successful integration of the BIOTRONIK Vascular Interventions deal and improved earnings crucial for the company's equity story. Investors are evaluating the impact of higher leverage on Teleflex's ability to absorb operational setbacks, especially given its currently stretched balance sheet and relatively weak interest coverage.
Teleflex Inc. stock underperforms Wednesday when compared to competitors
Teleflex Inc. (TFX) shares dropped 2.28% to $124.96 on Wednesday, extending losses for the third consecutive day. This underperformance occurred during a broader market decline, with the S&P 500 Index (SPX) falling 1.21% and the Dow Jones Industrial Average (DJIA) decreasing by 0.98%.
Mangrove Partners IM LLC Buys Shares of 256,726 Teleflex Incorporated $TFX
Mangrove Partners IM LLC has initiated a new position in Teleflex Incorporated (NYSE:TFX), purchasing 256,726 shares valued at approximately $31.3 million. This stake represents 2.6% of Mangrove's total holdings and 0.58% of Teleflex. The medical technology company recently reported stronger-than-expected Q4 earnings and revenue, issued a quarterly dividend, and received mixed analyst ratings with a "Hold" consensus.
Teleflex Inc. Stock (US8793691069): Quarterly earnings in focus after recent update
This article focuses on Teleflex Inc. (TFX) stock, highlighting how its recent quarterly earnings and guidance continue to influence investor sentiment and market expectations on the NYSE. It details Teleflex's business model as a medical technology company, its revenue drivers, profit dynamics, and strategic allocation of free cash flow, emphasizing the importance of procedure volumes and product innovation. The article also positions Teleflex within the broader U.S. healthcare equipment sector, discussing how its performance is analyzed against peers and external factors like regulatory changes.
Teleflex Issues New Senior Notes to Strengthen Capital Structure
Teleflex (TFX) has issued $500 million of 5.875% senior notes due January 15, 2032, to bolster its capital structure. These notes include various protections for bondholders like change-of-control repurchase clauses and covenants limiting corporate actions. Despite a "Buy" rating from analysts with a $160 price target, TipRanks' AI Analyst, Spark, rates TFX as "Neutral" due to recent profitability and revenue contraction, though it notes supportive technicals and management's constructive outlook.
Teleflex Inc. stock underperforms Tuesday when compared to competitors
Teleflex Inc. (TFX) shares dropped 1.71% on Tuesday, closing at $127.87. This underperformance occurred on a mixed trading day, with the Dow Jones Industrial Average rising but the S&P 500 Index falling. This marks the second consecutive day of losses for Teleflex stock.
Teleflex issues $500 million in 5.875% senior notes due 2032
Teleflex Incorporated announced the issuance of $500 million in 5.875% senior notes due January 2032. These unsecured senior obligations will pay interest semi-annually and are redeemable under specified conditions. The company's stock is considered undervalued by InvestingPro analysis, and it maintains a strong current ratio.
Teleflex (NYSE: TFX) sells $500M 5.875% senior notes due 2032
Teleflex Incorporated has issued $500 million in 5.875% senior notes due January 15, 2032. These unsecured notes pay interest semi-annually and are guaranteed by certain wholly-owned domestic subsidiaries. The offering provides Teleflex with long-dated, fixed-rate funding and includes flexible redemption and change-of-control provisions.
Teleflex Issues $500 Million 5.875% Senior Notes Due 2032 Under New Indenture
Teleflex (TFX) has issued $500 million of 5.875% senior notes due January 2032 under a new indenture. These notes, which are senior unsecured obligations, will pay interest semi-annually starting January 15, 2027, and are guaranteed by certain wholly-owned domestic subsidiaries. This agreement aims to raise capital and enhance the company's financial flexibility.
Teleflex Incorporated (TFX) Stock Analysis: Unlocking 11.81% Potential Upside in the Medical Device Sector
Teleflex Incorporated (NYSE: TFX), a medical device company, shows a potential upside of 11.81% according to analyst price targets, with an average target of $145.89. The company exhibits robust revenue growth of 32.30% and an attractive forward P/E of 12.37, despite a marginal return on equity and negative free cash flow. Analyst sentiment is cautiously optimistic, with strong buy and hold ratings, suggesting future capital appreciation for investors.
How Teleflex Incorporated (TFX) Affects Rotational Strategy Timing
This article analyzes Teleflex Incorporated (TFX) for rotational strategy timing, highlighting weak near-term sentiment and a mid-channel oscillation pattern. It presents AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with detailed signal analysis across different time horizons. The analysis identifies a significant risk-reward short setup targeting 10.5% downside.
How Teleflex Incorporated (TFX) Affects Rotational Strategy Timing
This article analyzes Teleflex Incorporated (TFX) using AI models, identifying a weak near-term sentiment with a mid-channel oscillation pattern. It presents three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis. The analysis highlights a significant risk-reward short setup targeting 10.5% downside.
Teleflex Inc. stock underperforms Thursday when compared to competitors
Teleflex Inc. (TFX) stock fell by 2.15% on Thursday, closing at $129.31, despite a strong performance by the overall stock market. Both the S&P 500 Index and the Dow Jones Industrial Average saw significant gains, rising 1.75% and 1.86% respectively. This marks the second consecutive day of losses for Teleflex Inc. shares.
Will Teleflex's (TFX) Note Refinancing and Freesolve Data Shift Its Acquisition-Led Innovation Narrative?
Teleflex (TFX) recently completed a private US$500 million offering of 5.875% senior notes due 2032 to refinance existing debt, aligning balance sheet management with its maturing interventional cardiology pipeline. This refinancing coincides with positive four-year clinical data for its Freesolve Resorbable Magnesium Scaffold, showing no new cardiac events. These developments may bolster the company's acquisition-led, innovation-focused investment narrative, despite ongoing integration risks with BIOTRONIK and potential margin pressures.
